Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice. “While immune checkpoint inhibitors, such as anti-PD1 and anti-CTLA4, are already in clinics and are used mainly as single agents, there are currently almost a thousand clinical...